Brief: Neuropace Announces Positive 18-Month NAUTILUS Trial Results In Idiopathic Generalized Epilepsy
08/12/2025 13:09
Dec 8 (Reuters) - Neuropace Inc NPCE.O: NEUROPACE ANNOUNCES POSITIVE 18-MONTH NAUTILUS TRIAL RESULTS IN IDIOPATHIC GENERALIZED EPILEPSY NEUROPACE INC - 77% MEDIAN REDUCTION IN GTC SEIZURES AT 18 MONTHS NEUROPACE: REMAINS ON TRACK TO SUBMIT NAUTILUS PMA SUPPLEMENT TO FDA FOR IGE INDICATION EXPANSION BY YEAR-END Source text: ID:nBw5ZsKJTa Further company coverage: NPCE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeuroPace
See all newsMedTech growth concerns likely to overshadow Q3 results, Leerink says
NeuroPace, Inc. reports results for the quarter ended June 30 - Earnings Summary
NeuroPace Q2 revenue slightly beats estimates
Brief: NeuroPace, Inc. Q2 EPS USD -0.18
NeuroPace, Inc. expected to post a loss of 21 cents a share - Earnings Preview